REG - SEGRO PLC - Director/PDMR Shareholding

SEGROAnnouncement

13/12/2019 14:00

RNS Number : 8566W
SEGRO PLC
13 December 2019
 


13 December 2019
SEGRO plc (the Company)
Dealing by Director
On 13 December 2019, the Company was notified of the following transaction by a Director. Following the transaction, the Director's beneficial holding is as follows:



Director


Date of purchase


Number of shares purchased


Purchase price per share
(pence)


Resultant beneficial holding




Sue Clayton


13 December 2019


7,000


860.3985


7,000



 
The Notification of Dealing Form provided in accordance with the requirements of the Market Abuse Regulation (2014/596/EU) in relation to the transaction listed above is set out below:



1.


Details of the person discharging managerial responsibilities / person closely associated




a)
 


Name


Sue Clayton




2.


Reason for the notification




a)
 


Position/status
 


Non-Executive Director




b)
 


Initial notification /Amendment
 


Initial




3.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)
 


Name
 


SEGRO plc




b)
 


LEI


213800XC35KGM9NFC641




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)
 


Description of the financial instrument, type of instrument


Ordinary Shares of 10 pence each




b)
 


Nature of the transaction


Purchase of shares




c)
 


Price(s) and volume(s)





Price


Volume


Total




£8.603985


7,000


£60,227.90








d)
 


Aggregated information


N/A




e)
 


Date of the transaction
 
 


13 December 2019




f)
 


Place of the transaction
 


London Stock Exchange (XLON)



 
 
Stephanie Murton
Legal Counsel
020 7451 9083




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHFXLFFKLFEFBK